scholarly journals PALIPERIDONE PALMITATE LONG-ACTING INJECTION IN SCHIZOPHRENIC PATIENTS: IMPROVED OF NEGATIVE SYMTONS AND METABOLIC RATES

2019 ◽  
Author(s):  
Eugenio Suarez ◽  
Maria Jose Abenza Abildua
Keyword(s):  
Paliperidone Palmitate ◽  
Metabolic Rates ◽  
Schizophrenic Patients ◽  
Long Acting

scholarly journals Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review

2021 ◽  
Vol 12 ◽  
Author(s):  
Amber N. Edinoff ◽  
Prithvi K. Doppalapudi ◽  
Claudia Orellana ◽  
Caroline Ochoa ◽  
Shelby Patti ◽  
...  
Keyword(s):  
Dose Interval ◽  
Paliperidone Palmitate ◽  
Critical Determinant ◽  
Once Daily ◽  
Schizophrenic Patients ◽  
Long Acting ◽  
Post Hoc ◽  
Antipsychotic Drug Treatment ◽  
Economic And Social Impacts ◽  
Risk Of Relapse

Given the typical age onset of schizophrenia, there are tremendous economic and social impacts that extend beyond the person and their families. One critical determinant of the diseases' impact is the patient's adherence to antipsychotic drug treatment. Approved in 2015 for the treatment of schizophrenia, paliperidone palmitate (Invega Trinza, a 3-month injection, noted as PP3M) is a second-generation long-acting injectable antipsychotic medication. Among the different formulations offered for palmitate paliperidone, including the 1 and 3-month formulations, the longer duration 3-month formulation was better at preventing relapse in schizophrenic patients. To date, different formulations of palmitate paliperidone that have been studied on relapse episodes of schizophrenia include once-daily extended-release oral paliperidone (ORAL paliperidone), once-monthly paliperidone palmitate (PP1M), and once-every-3-months paliperidone palmitate (PP3M). Post-hoc analyses show that patients who were withdrawn from PP1M paliperidone had the least risk of relapse, followed by patients withdrawn from PP3M and patients withdrawn from ORAL paliperidone. PP3M was better at preventing relapse compared to ORAL paliperidone. The results demonstrated that 50% of patients who were withdrawn from ORAL paliperidone, PP1M, or PP3M remained relapse-free for ~2, 6, and 13 months, respectively. Compared to PP1M, PP3M is just as safe and effective and has the added advantage of increased adherence related to a longer dose interval, decreasing the risk of relapse.

scholarly journals Accidental Overdose of Paliperidone Palmitate

2019 ◽  
Vol 2019 ◽  
pp. 1-3 ◽  
Author(s):  
Chiedozie Ojimba ◽  
Ayotomide Oyelakin ◽  
Taher Khandaker
Keyword(s):  
Side Effects ◽  
Plasma Level ◽  
Standard Dose ◽  
Selective Mutism ◽  
Paliperidone Palmitate ◽  
Receptor Sites ◽  
Schizophrenic Patients ◽  
Therapeutic Plasma Level ◽  
Disorganized Speech ◽  
Long Acting

Long-acting injectable (LAI) antipsychotics first introduced in 1960s are useful in the treatment of schizophrenic patients with poor medication adherence due to their maintaining feature of therapeutic plasma level without daily administration. Paliperidone Palmitate is one of such LAI antipsychotic drugs used due to its benefit of maintaining a therapeutic plasma level with four-week interval of injections. We report the case of a 21-year-old male with a history of mental illness that presented with selective mutism, disorganized speech, thought process and behavior, and auditory hallucinations who accidentally received 624 mg Paliperidone Palmitate intramuscularly with no reported side effects after 2 weeks of monitoring and observation. Paliperidone is a D2, 5HT2A receptor antagonist with additional antagonist activity at α-1 and α-2, H-1 receptor sites, and four metabolic pathways identified for its metabolism. Studies have reported adverse effects such as acute dystonia, acute renal failure, and cardiovascular abnormalities with Paliperidone overdose; however there is no reported literature on Paliperidone Palmitate overdose, though there have been reported cases of Paliperidone Palmitate side effects of hypersexuality and angioedema with the standard dose.

The role of long-acting antipsychotic treatment in schizophrenia with comorbid drug use. The case of paliperidone palmitate

2016 ◽  
Vol 33 (S1) ◽  
pp. S547-S548
Author(s):  
A. Portilla Fernández ◽  
L. Reula ◽  
E. Manrique Astiz ◽  
L.A. Núñez Domínguez ◽  
O. Arbeo Ruiz ◽  
...  
Keyword(s):  
Drug Use ◽  
Psychological Treatment ◽  
Oral Treatment ◽  
Good Alternative ◽  
Paliperidone Palmitate ◽  
Antipsychotic Treatment ◽  
Concomitant Treatment ◽  
Psychopharmacological Treatment ◽  
Schizophrenic Patients ◽  
Long Acting

The patient suffering a schizophrenic disorder with a comorbid drug use is a challenge for the technical team of psychiatrists who provide to control this disorder. In some guides that include a revision of the efficacy of several psychopharmacological and/or psychological treatment shows that there any treatment has no efficacy in this group of patients. But it suggests that long-acting antipsychotic may play a role in some cases with no adherence. We study prospectively some data in a group of patients of these characteristics treated with paliperidone palmitate as main psychopharmacological treatment, using as measurements of outcome the number of psychiatric admissions, dosage of oral treatment, use of drug before and after the beginning of Paliperdione Palmitate. Our results show that it exists a decrease of number of admissions, dosage of oral concomitant treatment and drug use, with a very good adherence and no dropouts in the follow-up. We conclude that Paliperidone Palmitate may be a very good alternative for the psychopharmacological treatment in schizophrenic patients with comorbid drug use.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients

2018 ◽  
Vol 38 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Frédéric Limosin ◽  
Drifa Belhadi ◽  
Denis Comet ◽  
Maud Pacou ◽  
Sophie Bouju ◽  
...  
Keyword(s):  
Paliperidone Palmitate ◽  
Schizophrenic Patients ◽  
Long Acting
Sign in / Sign up

Export Citation Format

Share Document